×

2-Benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments

  • US 20060004014A1
  • Filed: 06/21/2005
  • Published: 01/05/2006
  • Est. Priority Date: 06/21/2004
  • Status: Abandoned Application
First Claim
Patent Images

1. ) A compound of formula (I), embedded image wherein R1, R2 which may be identical or different, denote a group selected from among optionally substituted C1-C10-alkyl, C2-C10-alkenyl, C2-C10-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl, C3-C8-heterocycloalkyl, —

  • X-aryl, —

    X-heteroaryl, —

    X-cycloalkyl, —

    X-heterocycloalkyl, —

    NR8-aryl, —

    NR8-heteroaryl, —

    NR8-cycloalkyl, and —

    NR8-heterocycloalkyl, or a group selected from among hydrogen, halogen, COXR8, CON(R8)2, COR8 and XR8, or R1 and R2 together denote a 2- to 5-membered alkyl bridge which may contain 1 to 2 heteroatoms, R3 denotes hydrogen or a group selected from among optionally substituted C1-C12-alkyl, C2-C12-alkenyl, C2-C12-alkynyl, aryl, heteroaryl, C3-C12-cycloalkyl, C3-C12-cycloalkenyl, C7-C12-polycycloalkyl, C7-C12-polycycloalkenyl and C5-C12-spirocycloalkyl or R1 and R3 or R2 and R3 together denote a saturated or unsaturated C3-C4-alkyl bridge which may contain 1 to 2 heteroatoms, R4 denotes optionally substituted aryl or heteroaryl, R5 denotes a group selected from among hydrogen, CHO, XH, —

    X—

    C1-C2-alkyl and an optionally substituted C1-C3-alkyl group, R6 denotes a group selected from among hydrogen, NH2, XH, halogen and a C1-C3-alkyl group optionally substituted by one or more halogen atoms, R7 denotes hydrogen or —

    CO—

    C1-C4-alkyl, —

    CO—

    NH—

    C1-C4-alkyl, —

    CO—

    X—

    C1-C4-alkyl, and X in each case independently of one another denote O or S, R8 in each case independently of one another denote hydrogen or a group selected from among optionally substituted C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, benzyl and phenyl, R10 and R11 in each case independently of one another denote hydrogen or a group selected from among optionally substituted C1-C4-alkyl, or R10 and R11 together denote a 2-5 membered alkyl bridge, or the pharmacologically acceptable acid addition salt, solvate or hydrate thereof.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×